Home / Drugs / Starting with E /
indicationFor use as an adjunct therapy for patients with dementia
pharmacologyErgoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
mechanism of actionErgoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.
toxicitySymptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
absorptionRapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
half life3.5 hours
drug interactionsDesvenlafaxine: Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Telithromycin: Telithromycin may reduce clearance of Ergoloid mesylates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergoloid mesylates if Telithromycin is initiated, discontinued or dose changed.
Tipranavir: Tipranavir may increase the plasma concentration of Ergoloid mesylates. Concomitant therapy should be avoided.
Tramadol: Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Tranylcypromine: Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
Trazodone: Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Trimipramine: Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Venlafaxine: Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Voriconazole: Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergoloid mesylates by decreasing their metabolism. Concomitant therapy is contraindicated.
Zolmitriptan: Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergoloid mesylate, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.